Literature DB >> 34293055

Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes.

Marina Harada1, Tadashi Yamakawa1, Rie Kashiwagi1, Akeo Ohira1, Mai Sugiyama1, Yasuyuki Sugiura1, Yoshinobu Kondo1, Yasuo Terauchi2.   

Abstract

Lipid management, especially with respect to triglyceride (TG) metabolism, in patients with diabetes is not sufficient with current therapeutic agents, and new approaches for improvement are needed. Members of the angiopoietin-like protein (ANGPTL) family, specifically ANGPTL3, 4, and 8, have been reported as factors that inhibit lipoprotein lipase (LPL) activity and affect TGs. The present study investigated the association between lipid and glucose metabolism markers and the mechanism by which these proteins affect lipid metabolism. A total of 84 patients hospitalized for diabetes treatment were evaluated. Lipid and glucose metabolism markers in blood samples collected before breakfast, on the day after hospitalization, were analyzed. ANGPTL8 showed a significant positive correlation with TG values. HDL-C values displayed a significant positive correlation with ANGPTL3 but a negative correlation with ANGPTL4 and ANGPTL8. The results did not indicate a significant correlation among ANGPTL3, 4, and 8 levels. Thus, it is possible that the distribution of these proteins differs among patients. When patients were divided into groups according to the levels of ANGPTL3 and ANGPTL8, those with high levels of both ANGPTL3 and ANGPTL8 also had high levels of TG and small dense LDL-C/LDL-C (%). Multiple regression analysis indicated that low LPL, high ApoC2, high ApoC3, high ApoE, and high ANGPTL8 levels were the determinants of fasting hypertriglyceridemia. By contrast, no clear association was observed between any of the ANGPTLs and glucose metabolism markers, but ANGPTL8 levels were positively correlated with the levels of HOMA2-IR and BMI. Patients with high levels of both ANGPTL3 and ANGPTL8 had the worst lipid profiles. Among ANGPTL3, 4, and 8, ANGPTL8 is more important as a factor determining plasma TG levels. We anticipate that the results of this research will facilitate potential treatments targeting ANGPTL8 in patients with diabetes.

Entities:  

Year:  2021        PMID: 34293055     DOI: 10.1371/journal.pone.0255147

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  44 in total

1.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.

Authors:  Deepak L Bhatt; P Gabriel Steg; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle; Rebecca A Juliano; Lixia Jiao; Craig Granowitz; Jean-Claude Tardif; Christie M Ballantyne
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

Review 2.  Regulation of lipoprotein lipase by Angptl4.

Authors:  Wieneke Dijk; Sander Kersten
Journal:  Trends Endocrinol Metab       Date:  2014-01-04       Impact factor: 12.015

3.  ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.

Authors:  Viktoria Gusarova; Corey A Alexa; Yan Wang; Ashique Rafique; Jee Hae Kim; David Buckler; Ivory J Mintah; Lisa M Shihanian; Jonathan C Cohen; Helen H Hobbs; Yurong Xin; David M Valenzuela; Andrew J Murphy; George D Yancopoulos; Jesper Gromada
Journal:  J Lipid Res       Date:  2015-05-11       Impact factor: 5.922

4.  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Authors:  A Keech; R J Simes; P Barter; J Best; R Scott; M R Taskinen; P Forder; A Pillai; T Davis; P Glasziou; P Drury; Y A Kesäniemi; D Sullivan; D Hunt; P Colman; M d'Emden; M Whiting; C Ehnholm; M Laakso
Journal:  Lancet       Date:  2005-11-26       Impact factor: 79.321

5.  ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance.

Authors:  Jorge F Haller; Ivory J Mintah; Lisa M Shihanian; Panayiotis Stevis; David Buckler; Corey A Alexa-Braun; Sandra Kleiner; Serena Banfi; Jonathan C Cohen; Helen H Hobbs; George D Yancopoulos; Andrew J Murphy; Viktoria Gusarova; Jesper Gromada
Journal:  J Lipid Res       Date:  2017-04-15       Impact factor: 5.922

6.  Mice lacking ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis.

Authors:  Yan Wang; Fabiana Quagliarini; Viktoria Gusarova; Jesper Gromada; David M Valenzuela; Jonathan C Cohen; Helen H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

7.  Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.

Authors:  Frederick E Dewey; Viktoria Gusarova; Colm O'Dushlaine; Omri Gottesman; Jesus Trejos; Charleen Hunt; Cristopher V Van Hout; Lukas Habegger; David Buckler; Ka-Man V Lai; Joseph B Leader; Michael F Murray; Marylyn D Ritchie; H Lester Kirchner; David H Ledbetter; John Penn; Alexander Lopez; Ingrid B Borecki; John D Overton; Jeffrey G Reid; David J Carey; Andrew J Murphy; George D Yancopoulos; Aris Baras; Jesper Gromada; Alan R Shuldiner
Journal:  N Engl J Med       Date:  2016-03-02       Impact factor: 91.245

8.  Hepatic proprotein convertases modulate HDL metabolism.

Authors:  Weijun Jin; Xun Wang; John S Millar; Thomas Quertermous; George H Rothblat; Jane M Glick; Daniel J Rader
Journal:  Cell Metab       Date:  2007-08       Impact factor: 27.287

9.  A lipasin/Angptl8 monoclonal antibody lowers mouse serum triglycerides involving increased postprandial activity of the cardiac lipoprotein lipase.

Authors:  Zhiyao Fu; Abdul B Abou-Samra; Ren Zhang
Journal:  Sci Rep       Date:  2015-12-21       Impact factor: 4.379

10.  Increased ANGPTL3, 4 and ANGPTL8/betatrophin expression levels in obesity and T2D.

Authors:  Mohamed Abu-Farha; Irina Al-Khairi; Preethi Cherian; Betty Chandy; Devarajan Sriraman; Asma Alhubail; Faisal Al-Refaei; Abdulmohsen AlTerki; Jehad Abubaker
Journal:  Lipids Health Dis       Date:  2016-10-13       Impact factor: 3.876

View more
  3 in total

Review 1.  An updated ANGPTL3-4-8 model as a mechanism of triglyceride partitioning between fat and oxidative tissues.

Authors:  Ren Zhang; Kezhong Zhang
Journal:  Prog Lipid Res       Date:  2021-11-16       Impact factor: 16.195

2.  ANGPTL3 Is Involved in the Post-prandial Response in Triglyceride-Rich Lipoproteins and HDL Components in Patients With Coronary Artery Disease.

Authors:  Xin Guo; Zhijie Huang; Jin Chen; Jiarui Hu; Die Hu; Daoquan Peng; Bilian Yu
Journal:  Front Cardiovasc Med       Date:  2022-06-29

Review 3.  Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.

Authors:  Jelena Vekic; Aleksandra Zeljkovic; Aleksandra Stefanovic; Natasa Bogavac-Stanojevic; Ioannis Ilias; José Silva-Nunes; Anca Pantea Stoian; Andrej Janez; Manfredi Rizzo
Journal:  Pharmaceutics       Date:  2022-04-09       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.